Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has awarded the title of Associate Professor to Calliope Dendrou and Siim Pauklin.

Calli Dendrou and Siim Pauklin
Associate Professors Calliope Dendrou (l) and Siim Pauklin (r)

Associate Professor Calliope Dendrou focuses her research on immune-mediated inflammatory disease (IMID) pathology and therapy. The group investigates cellular mechanisms across tissues and diseases to identify targets for novel treatment development or for drug repurposing and to provide insights for patient stratification and drug positioning strategies. Calli is the Data Analysis Lead for the Oxford-Janssen Cartography Consortium, the Chan Zuckerberg Initiative (CZI) LEGACY Network, a Cancer Research UK discovery programme, and a new CZI initiative for spatial omics profiling of rare paediatric diseases.

On being named Associate Professor, she said: 'I am delighted and honoured to have been appointed Associate Professor. This award recognises our achievements thus far in IMID translational research and immune multiomics, and our motivation to achieve further impact in this important area. I would also like to take this opportunity to acknowledge the support of NDORMS, the Kennedy Institute of Rheumatology, Reuben College, many wonderful collaborators and colleagues, and my lab members who are a daily source of inspiration.'

Also named an Associate Professor, Siim Pauklin leads a group with research interests covering stem cell biology and cancer research. He particularly focuses on molecular mechanisms that regulate cancer stem cell formation with a view to uncovering mechanisms that can be targeted by novel and more efficient cancer therapeutics. He is a Cancer Research UK Career Development Fellow leading a research group in the Botnar Institute.

Siim said: 'I am honoured to have the Associate Professor title awarded to me. The University of Oxford has a special status in research and teaching among universities throughout the world and in the wider public, so it is great and quite uplifting to be part of University of Oxford through NDORMS and to contribute with my expertise.'